Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...
OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...
The question is not just substitution but how SC therapeutics integration will affect health care delivery at scale. The real question is can we afford to ignore a more efficient, patient-centered ...
Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...
The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results